Aimed to Serve the Emerging Psychedelic Market
 
April 29, 2021 — Dustin Robinson, Esq., CPA, the founding partner of one of the leading law firms in the psychedelic industry, in partnership with seasoned private equity investor Robert Velarde, has launched Iter Investments, a venture capital firm that will aim to deploy capital primarily in businesses operating in and around the burgeoning psychedelic industry. Robinson explains: “Our mission is to help entrepreneurs build great companies that use medical and scientific research to reimagine the health care industry’s approach to addressing mental health disorders.”
 
Robinson sits at the cross-section of many aspects of the psychedelic ecosystem. His law firm has been recognized by Psychedelic Invest as one of the top law firm that specializes in psychedelics. Robinson also co-founded Mr. Psychedelic Law, a non-profit focused on driving legal reform through medical and scientific research. Through Mr. Psychedelic Law, Robinson and his team have drafted various psychedelic bills and resolutions, including a Florida bill filed by State Representative Michael Grieco that seeks to legalize psilocybin mushrooms and decriminalize entheogenic plants and fungi. Dustin also co-founded other non-profits in the psychedelic space, including Mind Army, and currently represents the Psychedelic Pharmacists Association. Due to his active involvement in many areas within the psychedelic ecosystem, Robinson has early-stage businesses, investors, doctors, therapists, and other stakeholders reaching out to him for guidance in various capacities. 
 
When Robinson decided to launch Iter Investments, he teamed up with Robert Velarde. Velarde is a seasoned private equity investor with over 25 years of global private equity investment experience in a broad range of industries in US, Latin America, Europe, and Asia. Velarde earned his MBA from Harvard University; and has proven experience building and managing private markets investment platforms as a senior leader in institutional, family office, and impact investment firms. 
 
“I believe that Robert’s deep expertise in originating, structuring and managing direct private investments and managing funds, combined with my expertise in the psychedelic space, make us a unique partnership to capitalize and assist this emerging industry,” said Robinson. 
 
Next, Robinson and Velarde built an advisory board to assist the team with opportunity identification, diligence, and portfolio management: 
·Dr. Scott Fisher, MD, is the Psychiatric Lead for Iter Investments. He has his Certificate in Psychedelic Therapy Research from California Institute of Integral Studies; and he is the Lead Facilitator with Segal Clinic in the Usona FDA Phase 2 clinical trial assessing effectiveness of psilocybin for major depressive disorder.
·Dr. Michelle Weiner, DO, MPH, is the Clinical Lead for Iter Investments. Her practice includes psychedelic-assisted therapy through ketamine.
·Edgar Asebey, Esq., is the FDA Lead for Iter Investments. He has over two decades of experience in federal regulation of pharmaceuticals and biotechnology.
·David Wood, Esq., Ph.D., is the Intellectual Property Lead for Iter Investments. He specializes in patents and other intellectual property in the psychedelic space.
·Andrew Hall, Ph.D., is the Scientific Lead for Iter Investments. He has his PhD in Natural Products Chemistry and Pharmacognosy; and he is the Chief Science Officer of Green Scientific Labs.
·Matthew Savarick, is a mental and behavioral health executive, and is an expert in coaching high-performing individuals and teams to reach even higher levels of success.
 
Velarde explains, “Our advisory board represents the end-to-end psychedelic value chain. By creating what we consider to be a team of experts and professionals within the psychedelic industry, Iter Investments aims to provide investors with an unparalleled opportunity to access a broad range of emerging companies in the psychedelic sector. The psychedelic industry has received an increasing amount of acceptance and early-stage firms are looking to scale.  Many believe that there is a current funding gap between psychedelic drug research and mass commercialization. We look to serve that gap while aiming to offer portfolio companies what we consider to be expert guidance to support their growth and success.”
 
 
 
About Iter Investments
Iter Investments is a newly started investment firm that will aim to primarily deploy capital in and around the burgeoning psychedelic industry. Iter Investments will seek to invest with the mission of re-imagining how the mental health and wellness industry delivers care. For more information, visit www.iterinvestments.com or email contact@iterinvestments.com.
 


Aimed to Serve the Emerging Psychedelic Market
 
April 29, 2021 — Dustin Robinson, Esq., CPA, the founding partner of one of the leading law firms in the psychedelic industry, in partnership with seasoned private equity investor Robert Velarde, has launched Iter Investments, a venture capital firm that will aim to deploy capital primarily in businesses operating in and around the burgeoning psychedelic industry. Robinson explains: “Our mission is to help entrepreneurs build great companies that use medical and scientific research to reimagine the health care industry’s approach to addressing mental health disorders.”
 
Robinson sits at the cross-section of many aspects of the psychedelic ecosystem. His law firm has been recognized by Psychedelic Invest as one of the top law firm that specializes in psychedelics. Robinson also co-founded Mr. Psychedelic Law, a non-profit focused on driving legal reform through medical and scientific research. Through Mr. Psychedelic Law, Robinson and his team have drafted various psychedelic bills and resolutions, including a Florida bill filed by State Representative Michael Grieco that seeks to legalize psilocybin mushrooms and decriminalize entheogenic plants and fungi. Dustin also co-founded other non-profits in the psychedelic space, including Mind Army, and currently represents the Psychedelic Pharmacists Association. Due to his active involvement in many areas within the psychedelic ecosystem, Robinson has early-stage businesses, investors, doctors, therapists, and other stakeholders reaching out to him for guidance in various capacities. 
 
When Robinson decided to launch Iter Investments, he teamed up with Robert Velarde. Velarde is a seasoned private equity investor with over 25 years of global private equity investment experience in a broad range of industries in US, Latin America, Europe, and Asia. Velarde earned his MBA from Harvard University; and has proven experience building and managing private markets investment platforms as a senior leader in institutional, family office, and impact investment firms. 
 
“I believe that Robert’s deep expertise in originating, structuring and managing direct private investments and managing funds, combined with my expertise in the psychedelic space, make us a unique partnership to capitalize and assist this emerging industry,” said Robinson. 
 
Next, Robinson and Velarde built an advisory board to assist the team with opportunity identification, diligence, and portfolio management: 
·Dr. Scott Fisher, MD, is the Psychiatric Lead for Iter Investments. He has his Certificate in Psychedelic Therapy Research from California Institute of Integral Studies; and he is the Lead Facilitator with Segal Clinic in the Usona FDA Phase 2 clinical trial assessing effectiveness of psilocybin for major depressive disorder.
·Dr. Michelle Weiner, DO, MPH, is the Clinical Lead for Iter Investments. Her practice includes psychedelic-assisted therapy through ketamine.
·Edgar Asebey, Esq., is the FDA Lead for Iter Investments. He has over two decades of experience in federal regulation of pharmaceuticals and biotechnology.
·David Wood, Esq., Ph.D., is the Intellectual Property Lead for Iter Investments. He specializes in patents and other intellectual property in the psychedelic space.
·Andrew Hall, Ph.D., is the Scientific Lead for Iter Investments. He has his PhD in Natural Products Chemistry and Pharmacognosy; and he is the Chief Science Officer of Green Scientific Labs.
·Matthew Savarick, is a mental and behavioral health executive, and is an expert in coaching high-performing individuals and teams to reach even higher levels of success.
 
Velarde explains, “Our advisory board represents the end-to-end psychedelic value chain. By creating what we consider to be a team of experts and professionals within the psychedelic industry, Iter Investments aims to provide investors with an unparalleled opportunity to access a broad range of emerging companies in the psychedelic sector. The psychedelic industry has received an increasing amount of acceptance and early-stage firms are looking to scale.  Many believe that there is a current funding gap between psychedelic drug research and mass commercialization. We look to serve that gap while aiming to offer portfolio companies what we consider to be expert guidance to support their growth and success.”
 
 
 
About Iter Investments
Iter Investments is a newly started investment firm that will aim to primarily deploy capital in and around the burgeoning psychedelic industry. Iter Investments will seek to invest with the mission of re-imagining how the mental health and wellness industry delivers care. For more information, visit www.iterinvestments.com or email contact@iterinvestments.com.
 


Rating Indicates Wellington Regional as one of the Safest Hospitals in the Country
 
April 29 2021 – Wellington Regional Medical Center received an “A” grade in the spring 2021 Leapfrog Hospital Safety Grade, a national distinction recognizing Wellington Regional’s achievements protecting patients from errors, injuries, accidents and infections. 
 
“We are thrilled to be rated as an ‘A’ hospital by The Leapfrog Group,” said Pam Tahan, CEO, Wellington Regional Medical Center.  “Patient safety remains the top priority for Wellington Regional and earning an ‘A’ rating by one of the nation’s premier review organizations is an indication of our team’s commitment to providing the highest quality care possible.  The rating signifies that Wellington Regional is among the safest hospitals for patients in the nation.” 
 
The Leapfrog Group is an independent national watchdog organization committed to health care quality and safety. The Leapfrog Hospital Safety Grade assigns an “A,” “B,” “C,” “D,” or “F” grade to all general hospitals across the country and is updated every six months. It is the only hospital ratings program based exclusively on hospitals’ prevention of medical errors and other harms to patients in their care. 
 
“An ‘A’ safety grade is an elite designation that your community should be proud of,” said Leah Binder, president and CEO of The Leapfrog Group. “The past year has been extraordinarily difficult for hospitals, but Wellington Regional shows us it is possible to keep a laser focus on patients and their safety, no matter what it takes.”
 
Developed under the guidance of a national expert panel, the Leapfrog Hospital Safety Grade uses up to 27 measures of publicly available hospital safety data to assign grades to more than 2,700 U.S. acute-care hospitals twice per year. The Hospital Safety Grade’s methodology is peer-reviewed and fully transparent, and the results are free to the public.
 
 
About Wellington Regional Medical Center
Wellington Regional Medical Center is a 233-bed acute care hospital accredited by The Joint Commission. Celebrating more than 30 years of treating residents in Wellington and the surrounding community, the hospital offers a wide range of services, including comprehensive stroke care, comprehensive lung program, minimally invasive services, cardiac services, a birthing center and level III NICU, comprehensive women’s center, hepatobiliary surgical procedures, intraoperative radiation therapy, interventional procedures and a wellness and weight loss center. To learn more about the hospital, please visit www.wellingtonregional.com.
 
 
About The Leapfrog Group
Founded in 2000 by large employers and other purchasers, The Leapfrog Group is a national nonprofit organization driving a movement for giant leaps forward in the quality and safety of American health care. The flagship Leapfrog Hospital Survey and new Leapfrog Ambulatory Surgery Center (ASC) Survey collect and transparently report hospital and ASC performance, empowering purchasers to find the highest-value care and giving consumers the lifesaving information they need to make informed decisions. The Leapfrog Hospital Safety Grade, Leapfrog’s other main initiative, assigns letter grades to hospitals based on their record of patient safety, helping consumers protect themselves and their families from errors, injuries, accidents, and infections. 
 


Saymar Moran, RN
 
Saymar Moran, RN, is the ANM of Stepdown at Palmetto General Hospital. Her career in nursing has translated into 14 years of healthcare experience that has taken her through a variety of specialty departments and leading to her passion with the Stepdown services department. Saymar earned her nursing degree at Miami Dade College. During her spare time, she enjoys exercising, outdoor activities, arts, music, as well as spending time with family and friends. Saymar takes great pride in the community she has found a passion for serving his community and has continued to reside and practice his nursing career within his community.
 
Camilo Puerto, RN
 
Camilo Puerto, RN, is the Assistance Nurse Manager of Critical Care at Palmetto General Hospital. His career in nursing has translated into 6 years of healthcare experience that has taken him through a variety of specialty departments and leading to his passion in Critical Care. Camilo is responsible for the day-to-day operations of a 50-bed Critical Care and Neurological Intensive Care Unit Department.
Camilo earned his nursing degree at Chamberlain School of Nursing. At the start of the COVID pandemic, Camilo demonstrated his dedication to caring for our most critically ill Covid patients. He always treats his patients with compassion and empathy.
 
During his spare time, he enjoys exercising, outdoor activities, arts, music, as well as spending time with family and friends.

    



Saul Rivera, RN, BSN

Saul Rivera, R.N., B.S.N., is an Assistant Nurse Manager at North Shore Medical Center. He has been serving the community at North Shore for the past 15 years. Saul is in charge of overseeing a team of nurses. He also provides training, scheduling and mentoring. Saul earned his nursing degree at Ana. G Mendez University. During his spare time, he enjoys spending time with his family and exploring the world through travel. He has a passion for helping others and volunteering at local non-profits.